Form 4: VolitionRX Director Innes Receives Stock Units in Lieu of Cash Compensation

Director Guy Archibald Innes of VolitionRX Ltd. receives 16,022 restricted stock units (RSUs) in lieu of cash compensation, according to a recent SEC filing.

Summary

• Guy Archibald Innes, a director of VolitionRX Ltd., reported changes in beneficial ownership to the SEC.
• On June 1, 2024, Innes received 16,022 restricted stock units (RSUs) under the company's 2015 Stock Incentive Plan in lieu of cash compensation.
• The RSUs vest in installments on June 1, 2024, July 1, 2024, and August 1, 2024, with further time-based vesting on May 1, 2025, subject to continued service.
• Upon vesting, Innes will receive common stock equal to the number of vested RSUs.
• Innes also has indirect ownership of VolitionRX common stock through The Innes Family Bare Trust 2023 (1,000,000 shares), The Dill Faulkes Educational Trust Limited (356,000 shares), and shares held by his children (154,503 or 154,504 shares each).

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The receipt of RSUs is generally a positive sign, but the document itself is simply a disclosure.

Positives

• The receipt of RSUs by a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs implies an expectation of continued service from the director.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the alignment of management's interests with shareholders'.

Comparison to Industry Standards

• Granting stock options and restricted stock units (RSUs) to directors and executives is a common practice among publicly traded companies, particularly in the biotechnology sector, to incentivize performance and align interests with shareholders.
• The vesting schedule described is typical, with vesting occurring over several years to encourage long-term commitment.
• Comparable companies such as Exact Sciences and Guardant Health also utilize equity-based compensation as part of their overall executive compensation packages.

Stakeholder Impact

• Shareholders may view the grant of RSUs as a positive sign, aligning the director's interests with the company's long-term success.
• The director benefits from the potential future value of the RSUs, contingent on the company's performance.

Key Dates